Form 4: Catalyst Pharmaceuticals Director Acquires Shares Through Vesting of Restricted Stock Units

Director Donald A. Denkhaus acquired 1,413 shares of Catalyst Pharmaceuticals common stock through the vesting of restricted stock units.

Summary

• Donald A. Denkhaus, a director at Catalyst Pharmaceuticals, acquired 1,413 shares of common stock on December 9, 2024.
• The acquisition resulted from the vesting of restricted stock units.
• These restricted stock units vest in three equal tranches, with the first tranche vesting on December 8, 2024.
• The shares were delivered to Mr. Denkhaus on December 9, 2024.
• Following the transaction, Mr. Denkhaus directly owns 439,746 shares of Catalyst Pharmaceuticals common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed neutrally to positively. The acquisition of shares by a director can be seen as a positive sign of confidence in the company.

Positives

• The vesting of restricted stock units indicates that the director is meeting performance or time-based requirements.
• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a routine filing related to the vesting of equity compensation for a company director, which is a common practice in publicly traded companies.

Comparison to Industry Standards

• The vesting of restricted stock units is a standard form of equity compensation for directors and executives in publicly traded companies.
• The timing and vesting schedule of these units are typical for such arrangements.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it indicates director confidence in the company.

Key Dates

Keywords

Catalyst Pharmaceuticals, Director, Stock Acquisition, Restricted Stock Units, Share Vesting, Form 4, Insider Trading